The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

Biologically active GLP-1 7–36 amide is derived from proglucagon through post-translational processing. Proglucagon is generated throughout the small and large intestines in specialized ...

If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.

Creating a novel drug has always been a risky endeavor for biopharmaceutical companies. Developers and investors face ...

A drug normally used to treat diabetes can significantly reduce your risk of developing dementia, new research has revealed.

Explore how peptide drugs are changing the hundred-billion-level weight loss market, and how this landscape is changing as ...

It seems like a day doesn’t go by without another positive finding for the glucagon-like peptide 1 (GLP-1) receptoragonist ...

In patients older than 40 years, the type 2 diabetes drug class showed increased benefits over DPP-4 inhibitors at reducing ...

Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors may prevent dementia in middle-aged adults with diabetes, according to a ...

Researchers examine the role of GLP-2 in regulating food intake through its effects on gastrointestinal motility and satiety ...

Researchers aimed to explore whether newer diabetes medications like glucagon-like peptide-1 agonists and dipeptidyl ...